Damora Therapeutics, Inc. annual report, FY2021

Filing Overview

Filing: Form 10-K for the fiscal year ended December 31, 2021, filed February 17, 2022. The supplied metadata identifies Damora Therapeutics, Inc., but the filing text identifies the registrant as Galecto, Inc. (Nasdaq: GLTO). This entity discrepancy should be verified.

Business Context and Reporting Period

Galecto is a clinical-stage biotechnology company developing small-molecule inhibitors of galectin-3 and LOXL2 for fibrotic diseases and cancer. It has no approved products and has generated no product revenue. Its principal candidates are GB0139 for idiopathic pulmonary fibrosis, GB2064 for myelofibrosis, and GB1211 for liver cirrhosis and non-small-cell lung cancer.

  • GALACTIC-1: Phase 2b GB0139 trial in IPF.
  • MYLOX-1: Phase 2a GB2064 trial in myelofibrosis, initiated in the third quarter of 2021.
  • GULLIVER-2: Phase 1b/2a GB1211 trial in liver cirrhosis.
  • GALLANT-1: Planned Phase 2a GB1211 plus Roche’s atezolizumab in NSCLC.

Financial Performance and Liquidity

Metric20212020Change
Product revenue$0$0No change
Research and development expense$38.5 million$24.6 millionUp 56%
General and administrative expense$13.7 million$9.0 millionUp 52%
Total operating expenses$52.2 million$33.6 millionUp 55%
Loss from operations$(52.2) million$(33.6) millionLoss increased 55%
Net loss$(51.8) million$(34.8) millionLoss increased 49%
Basic and diluted loss per share$(2.05)$(7.62)Improved due primarily to higher share count
Net cash used in operating activities$(52.3) million$(38.2) millionUse increased
Cash, cash equivalents and marketable securities$109.2 million$163.6 million in cash and cash equivalentsDeclined

At December 31, 2021, cash and cash equivalents were $62.6 million and marketable securities were $46.7 million. Total assets were $122.2 million, total liabilities were $5.0 million, and stockholders’ equity was $117.2 million. The filing reports no debt financing outstanding; liabilities were primarily operating lease obligations and payables.

Investing cash outflows were $48.0 million, primarily reflecting purchases of marketable securities. There were no financing cash flows in 2021. The company stated that its existing cash, cash equivalents and marketable securities were expected to fund operating expenses and capital requirements into the second half of 2024, subject to assumptions that may prove incorrect.

Material Changes Versus the Prior Period

  • Research and development spending increased by $13.9 million, driven by higher clinical-trial activity, CMC spending, headcount and stock-based compensation.
  • General and administrative spending increased by $4.7 million, including higher personnel costs, stock-based compensation, insurance and director fees.
  • Operating cash burn increased by $14.1 million to $52.3 million.
  • The company invested excess cash in marketable securities; no marketable securities were held at December 31, 2020.
  • In March 2021, the GALACTIC-1 data safety monitoring board identified an imbalance in serious adverse events across study groups. Dosing was discontinued in patients receiving nintedanib or pirfenidone and in the GB0139 10 mg arm. Recruitment resumed in July 2021 using the 3 mg dose and placebo.
  • The company proposed reducing the GALACTIC-1 target population from up to 210 patients to 141 patients, subject to regulatory approval.
  • The company entered into a clinical trial supply agreement with Roche for the planned GALLANT-1 trial.
  • A material weakness in internal control over financial reporting identified for 2020 was reported as remediated as of December 31, 2021. Management concluded that disclosure controls and internal control over financial reporting were effective at year-end.

Outlook, Risks and Unusual Items

Management expects continued significant operating losses and increasing research and development and general and administrative expenses. Additional capital will be required to advance current candidates through clinical development and support operations beyond the company’s projected cash runway. The company has an effective shelf registration for up to $200.0 million of securities and an ATM program for up to $50.0 million of common stock; no ATM sales had occurred through December 31, 2021.

  • GALACTIC-1 enrollment was expected to finish in the second quarter of 2022, with topline results expected in mid-2023.
  • MYLOX-1 enrollment was expected to finish in the second quarter of 2022, with interim results in mid-2022 and topline results in the fourth quarter of 2022.
  • GULLIVER-2 enrollment was expected to finish in the second quarter of 2022, with topline results in the fourth quarter of 2022.
  • GALLANT-1 was expected to begin in the second quarter of 2022, with topline results in mid-2023.

Key risks include clinical failure or safety findings, patient-enrollment delays, COVID-19 disruptions, dependence on third-party CROs and manufacturers, regulatory uncertainty, competition, intellectual-property challenges, need for additional financing and potential dilution. The filing also identifies geopolitical risk relating to clinical-trial activity in Ukraine, as well as foreign-exchange, data-privacy, cybersecurity and reimbursement risks.

The filing reports no material legal proceedings. Lease commitments totaled $936,000, including $442,000 due within one year. Stock-based compensation expense was $4.5 million in 2021, with $12.5 million of unrecognized expense remaining at year-end.

Investor Verification Checklist

  • Verify whether the filing belongs to Galecto, Inc. or the company identified in the request metadata as Damora Therapeutics, Inc.
  • Reconcile the reported $109.2 million liquidity figure with the balance sheet components of cash, cash equivalents and marketable securities.
  • Assess whether the projected cash runway into the second half of 2024 remains credible after considering clinical-trial costs, enrollment delays and additional financing needs.
  • Review the complete GALACTIC-1 safety disclosures and subsequent regulatory response to the proposed reduction in enrollment.
  • Track enrollment, interim data and topline readouts for GALACTIC-1, MYLOX-1, GULLIVER-2 and GALLANT-1.
  • Evaluate the company’s ability to raise capital without material dilution and confirm utilization of the shelf registration or ATM program.
  • Confirm that the remediated internal-control weakness has not recurred in later filings.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.